NewsSource: EClinCloud

eCOA Pain Points, Back Off! 🤺 Back Off! 🤺 Back Off! 🤺

3 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: EClinCloud.

Article illustration

In our previous article, we noted that clinical trials in China are steadily accelerating toward an "electronic" era. Using mobile internet and cloud technologies together with smart hardware such as smartphones, tablets, and wearable devices, eCOA captures participant-reported data remotely, rapidly, and in real time, and will gradually replace traditional paper COA.

Article illustration


eCOA is an effective method for collecting data in Phase II, Phase III, and post-marketing clinical trials. It offers notable advantages in improving data quality and increasing patient compliance, and its value is increasingly recognized by regulatory authorities and sponsors. However, what key issues should sponsors pay close attention to when using eCOA?


☟ ☟ ☟

"Scales"


eCOA has been around for more than twenty years and has become the mainstream method for collecting key outcome data in clinical trials internationally. In recent years, eCOA has also begun to gain traction in China. However, because domestic scale development has lagged relatively behind, most scales currently used in clinical research are introduced from abroad. As a result, a growing number of sponsors are paying increasing attention to scale licensing and copyright management.


01

 Pain Points and Challenges in Using eCOA

(1) Some sponsors lack sufficient awareness of the importance of scale copyright and assume that scales can be used without obtaining copyright permission or translation by a professional translation agency, which will cause infringement and compliance issues;


(2) It is difficult to contact copyright holders, and even when reached, sponsors face various issues such as communication and confirmation, contract negotiation, and foreign currency payments. Obtaining copyright takes a long time and requires high investment;


(3) It is difficult to find a legitimate, professional translation and validation agency, making it impossible to ensure the compliance and validity of the translation;


(4) Even when different studies use the same scale, issues such as version updates, licensor transfers, and fee changes can occur, requiring fresh due diligence each time, which is time-consuming and labor-intensive, and still may not gather all of the information.


Using scales without purchased copyright or using scales improperly may result in copyright infringement against the scale rights holder, timeline delays that postpone the clinical trial, or lack of approval from the ethics committee, ultimately affecting the entire clinical trial.

 

For more articles on scales, click below:

"Scale Basics | Is the Scale in Your Hands Copyrighted?"

"Scale Basics | Scales Have Rightful Owners—Do Not Misappropriate or Substitute"



02

Advantages of EClinCloud eCOA for Scales

Our advantages are:


(1) Across therapeutic areas, EClinCloud has extensive experience in scale delivery, which can ensure scale compliance and security and effectively shorten delivery timelines.


(2) Professional, experienced medical project managers handle due diligence and delivery, bringing expertise not only in scale delivery processes but also in medical knowledge;


(3) Strong collaboration with copyright holders effectively ensures the timeliness of all types of scales;


(4) Long-term partnerships with translation vendors ensure the accuracy, timeliness, and cost-effectiveness of translations;


(5) Drawing on extensive scale experience and a professional medical background, the EClinCloud team can offer consulting advice from the sponsor's perspective;


(6) End-to-end service: if situations such as protocol amendments occur during a project, EClinCloud assists in communicating with copyright holders; if scale version updates or similar changes arise, EClinCloud also communicates with the sponsor in real time.


Driving the entire scale management process through science and technology while maintaining timely communication with sponsors.


Accurate medical evaluation results can help sponsors improve the success rate of clinical R&D.


| EClinCloud: Providing You with Professional Scale Management Services |

EClinCloud provides an integrated service spanning scale copyright acquisition, translation and validation, scale digitization, device provisioning, and rater training. Furthermore, backed by an experienced medical team and professional project managers responsible for developing training materials and conducting training, EClinCloud can better understand sponsor needs and provide consulting advice.



Article illustration

Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.